XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2024
Sep. 30, 2023
Current assets:    
Cash and cash equivalents $ 10,442,131 $ 7,151,800
Accounts receivable, net of allowance for credit losses of $75,000 at June 30, 2024 and September 30, 2023, respectively 513,871 255,502
Inventories 469,871 330,027
Prepaid expenses and other current assets 416,427 389,241
Total current assets 11,842,300 8,126,570
Property and equipment, net 530,735 838,270
Other assets:    
Restricted cash 750,000 750,000
Intangible assets 2,698,975 2,698,975
Operating right of use asset 868,081 1,237,762
Total assets 16,690,091 13,651,577
Current liabilities:    
Accounts payable and accrued liabilities 2,440,688 2,270,388
Operating lease liability, current 533,679 498,598
Deferred revenue 51,285 76,435
Total current liabilities 3,025,652 2,845,421
Long term accrued liabilities 31,467 31,467
Deferred revenue, long term 194,000 194,000
Operating lease liability, long term 334,402 739,162
Deferred tax liability, net 684,115 684,115
Warrants classified as a liability 186,000 4,285,000
Total liabilities 4,455,636 8,779,165
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of June 30, 2024 and September 30, 2023, 10,299,385 and 682,926 shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively 10,301 683
Additional paid in capital 318,757,698 307,397,623
Accumulated deficit (306,376,012) (302,447,147)
Applied DNA Sciences, Inc. stockholders' equity 12,391,987 4,951,159
Noncontrolling interest (157,532) (78,747)
Total equity 12,234,455 4,872,412
Total liabilities and equity 16,690,091 13,651,577
Series A Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively
Series B Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively